Could you tell us about the firm and your role there? Mr. Khuller: I’m the Vice President and Portfolio Manager at Letko Brosseau in Montreal, Canada. We manage about CAD18 billion in assets for our ...

Interview with Nicolas Poirier, CEO at OSE Immunotherapeutics a biotech with a compound that is a therapeutic cancer vaccine, ...

CEO Silviu Itescu explains how Mesoblast changes a disease that is fatal 70% or 90% to a disease that can be cured.

The Wall Street Transcript is a completely unique resource for investors and business researchers.

Could you tell me about Premier? Mr. Alkire: Sure. Premier is a health care improvement company. We have two different segments to our business. We have a supply chain segment and a performance ...

So let’s start with a brief history of the company and its mission. Mr. Pilcher: Sure. So Neuren is an interesting company, which has had a long history and a couple of incarnations. Twenty years ago ...

Nicolas Poirier is CEO at OSE Immunotherapeutics. He has been Chief Scientific Director and member of the management team of OSE Immunotherapeutics since 2016. He started his career at Tcl Pharma ...

First please introduce your firm and your coverage. You recently said that this is a very problematic market. Why so? What prompts the change in your outlook? Dr. Brozak: I am President of WBB ...

The big news is that the Fed cut rates by 50 basis points yesterday, and the market is dramatically rising. How is your coverage space looking? Dr. Phipps: Well, admittedly, the XBI, which is the ETF ...

Please give me an overview of the company and its services. Mr. Gonen: MediWound is a global leader in next generation enzymatic therapeutics for tissue repair. Our core active pharmaceutical ...

We spoke about two years ago. How would you compare today’s market to back then? Mr. Vandermosten: Two years ago would have been fall 2022, and I think we had seen about a year of pullback in the life ...